SCHEMBL23925971

SCHEMBL23925971

COc1cccc(-c2cccc(Oc3ccc4cn[nH]c4c3)n2)c1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.49
FGFR2 P21802 1/20 0.49
HSD17B14 Q9BPX1 1/20 0.47
TRPA1 O75762 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.41
RAF1 P04049 2/20 0.40
BRAF P15056 2/20 0.40
PKM P14618 1/20 0.39
AXL P30530 1/20 0.39
KDM4E B2RXH2 3/20 0.38
LMNA P02545 3/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TLR8 Q9NR97 1/20 0.37
MAPT P10636 5/20 0.37
ALDH1A1 P00352 3/20 0.37
ALOX15 P16050 3/20 0.37
ALOX12 P18054 3/20 0.37
MEN1 O00255 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30510804 1.00 FGFR1 (0.49) FGFR1FGFR2HSD17B14TRPA1TRPM8
SCHEMBL30500240 0.85 HSD17B14 (0.66) FGFR1FGFR2HSD17B14LMNAMAPT
SCHEMBL23926177 0.85 HSD17B14 (0.66) FGFR1FGFR2HSD17B14LMNAMAPT
SCHEMBL23943229 0.81 HSD17B14 (0.59) HSD17B14TRPA1NPC1RAB9ASMN1; SMN2
SCHEMBL23925997 0.80 FGFR2 (0.43) FGFR1FGFR2HSD17B14RAF1BRAF
SCHEMBL23943202 0.78 HSD17B14 (0.50) HSD17B14LMNANPC1RAB9ASMN1; SMN2
SCHEMBL23943218 0.77 HSD17B14 (0.55) HSD17B14TRPA1NPC1RAB9APDE4B
SCHEMBL23943401 0.76 HSD17B14 (0.45) HSD17B14LMNAALDH1A1MEN1KMT2A
SCHEMBL23943334 0.76 HSD17B14 (0.50) HSD17B14KDM4ELMNASMN1; SMN2MAPT
SCHEMBL25459530 0.75 HSD17B14 (0.44) HSD17B14BRAFLMNAALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
WO-2021211974-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2021-10-21 WO disclosed
WO-2021211974-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF HSD17B1, HSD17B3, HSD17B13 FGFR1 1591/4885FGFR2 3035/4885HSD17B14 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.